View in EDS HTML Full Text PDF Full Text

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.

Saved in:
Bibliographic Details
Title: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.
Authors: Brose MS; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA, United States., Keam B; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea., Krajewska J; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland., Hoff AO; Department of Endocrinology, Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil., Vaisman F; Department of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil., Lin CC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Hitre E; Department of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary., Bowles DW; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States., Robinson B; Department of Medicine, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia., Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Ngamphaiboon N; Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Guo X; Department of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States., Simmons A; Department of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States., Williamson D; Department of Biostatistics, Exelixis, Inc., Alameda, CA, United States., Andrianova S; Department of Late Phase Clinical Development, Exelixis, Inc., Alameda, CA, United States., Berry N; Department of Medical Affairs, Exelixis, Inc., Alameda, CA, United States., Capdevila J; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain.
Source: Frontiers in oncology [Front Oncol] 2026 Mar 04; Vol. 16, pp. 1748566. Date of Electronic Publication: 2026 Mar 04 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41858341
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Brose+MS%22">Brose MS</searchLink>; Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Jefferson University, Philadelphia, PA, United States.<br /><searchLink fieldCode="AU" term="%22Keam+B%22">Keam B</searchLink>; Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Krajewska+J%22">Krajewska J</searchLink>; Department of Nuclear Medicine and Endocrine Oncology, Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland.<br /><searchLink fieldCode="AU" term="%22Hoff+AO%22">Hoff AO</searchLink>; Department of Endocrinology, Instituto do Cancer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Vaisman+F%22">Vaisman F</searchLink>; Department of Endocrinology, Instituto Nacional de Câncer, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Lin+CC%22">Lin CC</searchLink>; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Hitre+E%22">Hitre E</searchLink>; Department of Medical Oncology, The Multidisciplinary Head and Neck Cancer Center, Országos Onkológiai Intézet, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Bowles+DW%22">Bowles DW</searchLink>; Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.<br /><searchLink fieldCode="AU" term="%22Robinson+B%22">Robinson B</searchLink>; Department of Medicine, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Sherman+SI%22">Sherman SI</searchLink>; Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, United States.<br /><searchLink fieldCode="AU" term="%22Ngamphaiboon+N%22">Ngamphaiboon N</searchLink>; Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.<br /><searchLink fieldCode="AU" term="%22Guo+X%22">Guo X</searchLink>; Department of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States.<br /><searchLink fieldCode="AU" term="%22Simmons+A%22">Simmons A</searchLink>; Department of Translational Medicine and Bioinformatics, Exelixis, Inc., Alameda, CA, United States.<br /><searchLink fieldCode="AU" term="%22Williamson+D%22">Williamson D</searchLink>; Department of Biostatistics, Exelixis, Inc., Alameda, CA, United States.<br /><searchLink fieldCode="AU" term="%22Andrianova+S%22">Andrianova S</searchLink>; Department of Late Phase Clinical Development, Exelixis, Inc., Alameda, CA, United States.<br /><searchLink fieldCode="AU" term="%22Berry+N%22">Berry N</searchLink>; Department of Medical Affairs, Exelixis, Inc., Alameda, CA, United States.<br /><searchLink fieldCode="AU" term="%22Capdevila+J%22">Capdevila J</searchLink>; Department of Medical Oncology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), IOB Quiron-Teknon, Barcelona, Spain.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2026 Mar 04; Vol. 16, pp. 1748566. <i>Date of Electronic Publication: </i>2026 Mar 04 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41858341
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2026.1748566
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1748566
    Titles:
      – TitleFull: Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF status.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Brose MS
      – PersonEntity:
          Name:
            NameFull: Keam B
      – PersonEntity:
          Name:
            NameFull: Krajewska J
      – PersonEntity:
          Name:
            NameFull: Hoff AO
      – PersonEntity:
          Name:
            NameFull: Vaisman F
      – PersonEntity:
          Name:
            NameFull: Lin CC
      – PersonEntity:
          Name:
            NameFull: Hitre E
      – PersonEntity:
          Name:
            NameFull: Bowles DW
      – PersonEntity:
          Name:
            NameFull: Robinson B
      – PersonEntity:
          Name:
            NameFull: Sherman SI
      – PersonEntity:
          Name:
            NameFull: Ngamphaiboon N
      – PersonEntity:
          Name:
            NameFull: Guo X
      – PersonEntity:
          Name:
            NameFull: Simmons A
      – PersonEntity:
          Name:
            NameFull: Williamson D
      – PersonEntity:
          Name:
            NameFull: Andrianova S
      – PersonEntity:
          Name:
            NameFull: Berry N
      – PersonEntity:
          Name:
            NameFull: Capdevila J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 03
              Text: 2026 Mar 04
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 16
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1